Socio-demographic profile and help-seeking behaviour of buprenorphine abusers in Singapore

Annals of the Academy of Medicine Singapore

Volumn 35, Issue 7, 2006, Pages 451-456

  Winslow, Munidasa ^a   Ng, Wei Ling ^a   Mythily, Subramaniam ^a   Song, Guo ^a   Yiong, Huak Chan ^b  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Buprenorphine; Dependence; Drug abuse; Opiate

Indexed keywords

BUPRENORPHINE; CANNABIS; GLUE; ILLICIT DRUG;

ADULT; ANAMNESIS; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG ABUSE; FEMALE; HELP SEEKING BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; QUESTIONNAIRE; SINGAPORE;

EID: 33749016036     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. AIHW, Australian Institute of Health, Welfare. 1998 National Drug Strategy Household Survey: First Results. Canberra, Australia: AIHW, 1999.
2. EMCDDA, European Monitoring Centre for Drugs, Drug Addiction. Annual report on the state of the drugs problem in the European Union. Luxembourg: Office for official publications of the European Communities, 1999.
3. Mark TL, Woody GE, Juday T, Kleber HD. The economic costs of heroin addiction in the United States. Drug Alcohol Depend 2001;61:195-206.
4. Kleber HD, Riordan CE. The treatment of narcotic withdrawal: a historical Review. J Clin Psychiatry 1982;43:30-4.
5. Best D, Gossop M, Marsden J, Farrell M, Strang J. Time of day of methadone consumption and illicit heroin use. Drug Alcohol Depend 1997;49:49-54.
6. Kreek MJ, LaForge KS, Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov 2002;1:710-26.
7. Cowan A, Lewis JW, McFarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977;60:537-45.
8. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55:569-80.
9. Nath RP, Upton RA, Everhart ET, Cheung P, Shwonek P, Jones RT, et al. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablets and liquid formulations. J Clin Pharmacol 1999;39:619-23.
10. Lintzeris N, Clark N, Muhleisen P, Ritter A. National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Heroin Dependence. Canberra, Australia: Department of Health and Aged Care, 2001.
11. Bigelow GE, Preston KL. Assessment of buprenorphine in a drug discrimination procedure in humans. NIDA Res Monogr 1992;121:28-37.
12. Jones HE, Bigelow GE, Preston KL. Assessment of opioid partial agonist activity with a three-choice hydromorphone dose-discrimination procedure. J Pharmacol Exp Ther 1999;289:1350-61.
13. Sung S, Conry JM. Role of buprenorphine in the management of heroin addiction. Ann Pharmacother 2006;40:501-5.
14. Sullivan LE, Chawarski M, O'Connor PG, Schottenfeld RS, Fiellin DA. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment? Drug Alcohol Depend 2005;79:113-6.
15. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003;361:662-8.
16. Lavelle TL, Hammersley R, Forsyth A. The use of buprenorphine and temazepam by drug injectors. J Addict Dis 1991;10:5-14.
17. O'Connor J, Moloney E, Travers R, Campbell A. Buprenorphine abuse among opiate addicts. Br J Addict 1988;83:1085-7.
18. Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP. Injecting misuse of buprenorphine among French drug users. Addiction 2001;96:267-72.
19. Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003;69:175-81.
20. Gouny P, Gaitz JP, Vayssairat M. Acute hand ischemia secondary to intraarterial buprenorphine injection: treatment with iloprost and dextran-40 - a case report. Angiology 1999;50:605-6.
21. Wisniewski B, Perlemuter G, Buffet C. Acute hepatitis following intravenous buprenorphine injection as a substitute drug in a drug-addict (French). Gastroenterol Clin Biol 2001;25:328-9.
22. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int 2001;121:65-9.
23. Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005;100:197-205.
24. Waller BF, Brownlee WJ, Roberts WC. Self-induced pulmonary granulomatosis. A consequence of intravenous injection of drugs intended for oral use. Chest 1980;78:90-4.
25. Loo HW, Yam AK, Tan TC, Peng YP, Teoh LC. Severe upper limb complications from parenteral abuse of Subutex. Ann Acad Med Singapore 2005;34:575-8.
26. Gueye PN, Borron SW, Risede P, Monier C, Buneaux F, Debray M, et al. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicol Sci 2002;65:107-14.
27. Haydon E, Rehm J, Fischer B, Monga N, Adlaf E. Prescription drug abuse in Canada and the diversion of prescription drugs into the illicit drug market. Can J Public Health 2005;96:459-61.
28. Marantz PR, Linzer M, Feiner CJ, Feinstein SA, Kozin AM, Friedland GH. Inability to predict diagnosis in febrile intravenous drug abusers. Ann Intern Med 1987;106:823-8.
29. Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict 2004;13:42-66.
30. Bell J, Byron G, Gibson A, Morris A. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. Drug Alcohol Rev 2004;23:311-7.
31. Ministry of Health Clinical Practice Guidelines. Treatment of Opiate Dependence. Singapore: MOH, 2005.